GlassScriptPhysician profile
Collin Maloney
NPI 1831505148
$56,966.06
in general payments reported to CMS, 2019-2025
24 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41K · 2022: $13K · 2023: $724 · 2024: $1,187 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,406.18 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $20,352.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $4,026.74 | 2022 | |
| Allergan, INC. | $2,189.84 | 2021-2022 | |
| Pfizer INC. | $675.36 | 2023-2025 | |
| Ucb, INC. | $444.60 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Teva Pharmaceuticals USA, INC. | $282.39 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $275.42 | 2021-2025 | Kisunla, Emgality, Amyvid |
| Catalyst Pharmaceuticals, INC. | $234.39 | 2023-2025 | Fycompa |
| Sk Life Science, INC. | $208.21 | 2021-2025 | |
| Biogen, INC. | $133.64 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $115.09 | 2021 | |
| Eisai INC. | $112.04 | 2022-2024 | |
| Neurelis, INC. | $108.22 | 2021-2025 | Valtoco |
| Celgene Corporation | $61.66 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $54.40 | 2025 | Ultomiris |
| Genentech USA, INC. | $53.03 | 2021-2022 | |
| Amgen INC. | $46.00 | 2021-2024 | Aimovig |
| Sunovion Pharmaceuticals INC. | $43.31 | 2021 | |
| Lundbeck LLC | $42.83 | 2022-2024 | Vyepti |
| Upsher-Smith Laboratories LLC | $28.12 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.71 | 2021 | |
| Abbott Laboratories | $24.31 | 2023 | Infinity |
| Sumitomo Pharma America, INC. | $23.46 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Maloney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.